logo-loader

Poolbeg Pharma Driving forward R&D programmes while seeking partners

Last updated: 18:25 02 Nov 2023 AEDT, First published: 18:23 02 Nov 2023 AEDT

Driving forward R&D programmes while seeking partners
 
POLB 001 status

POLB 001 is a small molecule immunomodulator targeting Cytokine Release Syndrome (CRS) experience in severe influenza and other acute inflammatory conditions. The most recent data from the LPS challenge study earlier this year showed that it effectively reduces multiple inflammatory cytokines in a dose-dependent manner and has a good safety profile. Based on WHO data, Poolbeg estimates there may be 3-5mln severe influenza cases a year globally. The company has been granted patents in the US and Europe out to 2038.

The opposition hearing scheduled by the European Patent Office relating to a challenge to the company's European patent (Immunomodulator I), was withdrawn in September 2023. This has now favourably concluded this matter with the patent maintained as granted. Immunomodulators I and II cover the use of P38 MAP kinase inhibitors for treatment of severe influenza and hypercytokinaemia — the uncontrolled and excessive release of pro-inflammatory signaling molecules (cytokines) that causes severe adverse physiological effects.

The company has a worldwide license to IP covering POLB 001 for all uses, but is expanding this IP protection to cover the use of p38 MAP kinase inhibitor class including for uses in oncology. In particular, it could be used to mitigate CRS, a common side effect to some oncology treatments, particularly CAR T cell therapy where it is seen in up to 95% of treatments. The most severe cases are life-threatening and can require intensive care support.

Poolbeg recently noted that as a result of its discussions with prospective partners, it is actively exploring a potential new indication for POLB 001 in oncology beyond CAR T. This could open up a further market for POLB 001. Development towards a clinical trial to advance POLB 001 in oncology is ongoing. Company partnering discussions about this molecule are ongoing.

Exhibit 1 - Cytokine Release Syndrome mechanism
Source: Poolbeg Investor Presentation

AI-assisted development

Poolbeg has collaborated with CytoReason and OneThree Biotech to utilise the companies' AI technologies to identify novel drug targets and treatments for influenza and Respiratory Syncytial Virus (RSV), respectively.

Lab-based validation is ongoing and management expects outputs for the RSV programme later this year, with the commencement of the influenza programme in 2024. The AI-led approach to drug discovery could enable faster and lower cost identification of drug targets, reducing risk and increasing likelihood of success.

Oral delivery platform

Poolbeg's oral delivery platform aims to target markets for vaccine delivery and the treatment of metabolic diseases using its licensed and validated encapsulation technology. These could be important markets for generating early revenue.

The EncOVac consortium, led by Poolbeg, was awarded €2.3mln in non-dilutive grant funding (which does not contribute to year-end cash figure) from the Irish government and has moved into the encapsulation validation phase. Management expects this to be completed in H2 2023. This technology platform covers multiple infectious diseases and could be an important commercial opportunity for the company.

The company's GLP-1 agonist for the treatment of metabolic diseases such as diabetes and obesity is progressing towards a proof-of-technology exploratory study to show that it can be delivered orally in humans. The trial is due to commence in H1 2024.

Exhibit 2 - Poolbeg product pipeline
Source: Poolbeg investor presentation
NO INVESTMENT ADVICE

Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) and this website (the Site) on the terms set out in this disclaimer, together with all other terms and conditions, disclaimers and other notices displayed elsewhere on this Site.

It is important for you to know that:

(a) none of the Content is, or is intended to be, general or personal advice

(b) the principal purpose of the Content is to provide factual information only and to comment on news;

(c) the Content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including in respect of any particular security, portfolio of securities, transaction or investment strategy, and must not be relied upon by you as such;

(d) in providing you with the Content, we have not considered your objectives, financial situation or needs; and

(e) you should make your own enquiries and obtain your own independent advice prior to making any financial decisions.

The Content contains data (including but not limited to prices, statistics and calculated information) obtained from a variety of third party sources (Third Party Data). The Company does not make any representation or warranty that any of the Content, including the Third Party Data, will be reliable, accurate or complete. The Company disclaims all responsibility and liability arising in any way from any errors or omissions in the Content, including the Third Party Data, including any loss you may incur in connection with any action or decision made by you in reliance upon the Content or Third Party Data.

In certain circumstances the Company, its related bodies corporate, or their affiliates, may have received, or be entitled to receive, financial or other consideration in connection with providing information about certain entities on the Site, which may include the above Content.

FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:

This document is published by Proactive Research and its contents have not been approved as a financial promotion by Proactive Investors Limited or any other FCA authorised person. This communication is made on the basis of the 'journalist exemption' provide for in Article 20 of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and having regard to the FCA rules, and in particular PERG 8.12.

Where the note contains a ‘buy, sell, hold’ recommend, Proactive Investors Limited is authorised to provide investment advice as defined by Article 53 of the RAO

FOR OUR FULL DISCLAIMER CLICK HERE

Poolbeg Pharma Plc: Further expansion of AI-based R&D

Proactive research analyst Robin Davidson joined Proactive's Katie Pilbeam to discuss his latest research note on Poolbeg Pharma PLC (AIM:POLB). Davidson said in his note that Poolbeg's deal with the Israeli artificial intelligence (AI)-based biotech CytoReason to conduct a drug discovery...

on 28/3/22